[Improvements in palliative treatment of colorectal carcinoma].
Wein
A
A
Medizinischen Klinik, Friedrich-Alexander-Universität Erlangen-Nürnberg. axel.wein@med1.med.uni-erlangen.de
Riedel
C
C
Hanke
B
B
Lampert
S
S
Brückl
W
W
Reingruber
B
B
Hohenberger
W
W
Hahn
E G
EG
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D010166:Palliative Care; D015996:Survival Rate
D000970:Antineoplastic Agents; D002955:Leucovorin; D005472:Fluorouracil